Comorbid major depressive disorder and fibromyalgia syndrome: A case report highlighting diagnostic challenges and successful multidisciplinary management

Abstract

Herein, we report the successful management of a 63-year-old woman with comorbid major depressive disorder (MDD) and fibromyalgia syndrome (FMS). The patient exhibited a 3-year history of generalized pain, fatigue, poor sleep, and depression. Initially diagnosed with MDD, persistent symptoms led to an additional diagnosis of FMS. The treatment involved a multidisciplinary approach involving pharmacological interventions (venlafaxine, pregabalin, and lorazepam) and non-pharmacological strategies (psychotherapy and electroacupuncture). Significant improvement was observed in depressive and pain symptoms. By day 15, the patient exhibited marked improvement in Hamilton Depression Rating Scale-24 (40 - 14), Hamilton Anxiety Rating Scale (27 - 11), and Visual Analog Scale pain scores (8 - 0). The 3-month follow-up revealed sustained improvement, and the patient resumed normal daily activities. This case emphasizes the importance of thorough evaluation, consideration of comorbid conditions, and the effectiveness of a multidisciplinary approach in managing complex cases of comorbid MDD and FMS. Furthermore, personalized treatment strategies are required to achieve optimal long-term outcomes.

Keywords

Comorbid / Major depressive disorder / Fibromyalgia syndrome / Chronic pain / Multidisciplinary management

Funding

None.

Conflict of interest

The authors declare that they have no competing interests.

References

[1] Clauw DJ. Fibromyalgia: A clinical review. JAMA. 2014; 311(15):1547-1555. doi: 10.1001/jama.2014.3266

[2] Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010; 62(5):600-610. doi: 10.1002/acr.20140

[3] Gracely RH, Ceko M, Bushnell MC. Fibromyalgia and depression. Pain Res Treat. 2012;2012:486590. doi: 10.1155/2012/486590

[4] Fietta P, Fietta P, Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed. 2007; 78(2):88-95.

[5] Maletic V, Raison CL. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci (Landmark Ed). 2009; 14(14):5291-5338. doi: 10.2741/3598

[6] Häuser W, Ablin J, Fitzcharles MA, et al. Fibromyalgia. Nat Rev Dis Primers. 2015;1:15022. doi: 10.1038/nrdp.2015.22

[7] Aguglia A, Salvi V, Maina G, Rossetto I, Aguglia E. Fibromyalgia syndrome and depressive symptoms: Comorbidity and clinical correlates. J Affect Disord. 2011; 128(3):262-266. doi: 10.1016/j.jad.2010.07.004

[8] Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017; 76(2):318-328. doi: 10.1136/annrheumdis-2016-209724

[9] Iacobucci G. NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms. BMJ. 2019;367:l6103. doi: 10.1136/bmj.l6103

[10] Arumugam V, MacDermid JC. Appraisal of clinical practice guideline: EULAR revised recommendations for the management of fibromyalgia. J Physiother. 2019; 65(2):112. doi: 10.1016/j.jphys.2019.01.003

[11] Bote ME, García JJ, Hinchado MD, Ortega E. Inflammatory/ stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation. 2012; 19(6):343-351. doi: 10.1159/000341664